Cannabigerol (CBG) is an emerging cannabinoid with increasing popularity, especially for its potential anxiety and depression-reducing effects as seen in preclinical studies. However, clinical evidence in humans has been limited. To address this gap, a recent double-blind, placebo-controlled cross-over trial was conducted with 34 healthy adult participants. The study aimed to assess the acute effects of CBG on anxiety, stress, and mood, and to determine whether CBG produces any subjective drug effects or impairs motor and cognitive functions. The trial involved two sessions for each participant, with a one-week washout period between them, where participants were administered either 20 mg of hemp-derived CBG or a placebo tincture.

During the trial, participants completed various assessments at different stages: before taking the product (T0), after ingestion and an online survey (T1), following the Trier Social Stress Test (T2), and after completing a verbal memory test and the DRUID app for cognitive and motor impairment (T3). The results indicated that CBG significantly reduced anxiety and stress compared to the placebo, with a notable reduction in anxiety levels and stress ratings. Additionally, CBG enhanced verbal memory, suggesting a positive impact on cognitive functions. Importantly, there were no reported subjective drug effects such as intoxication, dry mouth, or increased appetite, and no evidence of cognitive or motor impairment.

The study's findings are significant as they suggest that CBG may be a viable option for reducing anxiety and stress without the adverse effects commonly associated with other cannabinoids like THC. However, the study has limitations, including the relatively small sample size, the use of a single dose, and the lack of physiological measures for stress. Future research with larger samples, varying doses, and comprehensive assessments, including physiological markers, will be crucial to confirm these results and explore CBG's potential therapeutic applications for anxiety and mood disorders in clinical populations.